Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/aramis_695/public/wp-includes/functions.php on line 6121
Aramis Biosciences - Disease-Modifying Therapy for Ocular Surface Disease
Skip to content

Disease‑Modifying Therapy for Ocular Surface Disease

While 17.8 million people have been diagnosed with Dry Eye Disease in the United States…

Fewer than 1 million (1 in 20) are currently treated with an FDA-approved product; presumably due to questionable efficacy and tolerability limitations.

Patients infographic

Less than 5% (1 in 20) of Dry Eye Disease patients are currently treated with a FDA-approved product

Aramis Biosciences is a clinical-stage immuno‑ophthalmology biopharmaceutical company committed to the development of disease‑modifying therapy for ocular surface disease

Learn more about Aramis Biosciences

News

See all

Events

There are no upcoming events.

See all

Get in touch

Please provide a brief description of your inquiry and we’ll get back to you as soon as we can.